Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, vol.64, issue.1, pp.73-84, 2016. ,
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease, Annual Review of Physiology, vol.78, issue.1, pp.181-205, 2016. ,
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease, Gastroenterology, vol.158, issue.7, pp.1999-2014.e1, 2020. ,
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nature Genetics, vol.40, issue.12, pp.1461-1465, 2008. ,
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease, Nature Genetics, vol.46, issue.4, pp.352-356, 2014. ,
Genome-Wide Association Study Identifies Variants Associated With Histologic Features of Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.139, issue.5, pp.1567-1576.e6, 2010. ,
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent, Gastroenterology, vol.150, issue.5, pp.1219-1230.e6, 2016. ,
Complications, morbidity and mortality of nonalcoholic fatty liver disease, Metabolism, vol.111, p.154170, 2020. ,
Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study, Clinical Gastroenterology and Hepatology, vol.18, issue.10, pp.2324-2331.e4, 2020. ,
Non?alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study, Journal of Gastroenterology and Hepatology, vol.35, issue.5, pp.833-839, 2019. ,
Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease, Medicine, vol.96, issue.18, p.e6712, 2017. ,
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis, Journal of Hepatology, vol.65, issue.3, pp.589-600, 2016. ,
Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis, Scientific Reports, vol.6, issue.1, p.33386, 2016. ,
Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis, Scientific Reports, vol.9, issue.1, p.11124, 2019. ,
Atherosclerosis, Nature Reviews Disease Primers, vol.5, issue.1, p.56, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-01207988
Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study, Gut, vol.68, issue.9, pp.1667-1675, 2018. ,
Nonalcoholic Fatty Liver Disease Is Associated With Arterial Distensibility and Carotid Intima-Media Thickness: (from the Multi-Ethnic Study of Atherosclerosis), The American Journal of Cardiology, vol.124, issue.4, pp.534-538, 2019. ,
Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta?Analysis, Hepatology Communications, vol.2, issue.8, pp.877-887, 2018. ,
Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study, Gut, vol.66, issue.2, pp.323-329, 2016. ,
Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old, BMC Cardiovascular Disorders, vol.18, issue.1, p.147, 2018. ,
Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non?invasive score, Liver International, vol.40, issue.4, pp.806-814, 2020. ,
Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil, Atherosclerosis, vol.284, pp.59-65, 2019. ,
Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study, Journal of Hepatology, vol.68, issue.5, pp.1018-1024, 2018. ,
The association between liver fat and systemic calcified atherosclerosis, Journal of Vascular Surgery, vol.71, issue.1, pp.204-211.e4, 2020. ,
Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter, Journal of Gastroenterology, vol.54, issue.3, pp.271-280, 2018. ,
Association Between Nonalcoholic Fatty Liver Disease and Carotid Artery Inflammation Evaluated by 18F-Fluorodeoxyglucose Positron Emission Tomography, Angiology, vol.66, issue.5, pp.472-480, 2014. ,
Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by 18F-fluorodeoxyglucose positron emission tomography, Metabolism, vol.67, pp.72-79, 2017. ,
Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids, JCI Insight, vol.4, issue.16, p.127902, 2019. ,
Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease, Hepatology Communications, vol.3, issue.4, pp.587-596, 2019. ,
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits, PLoS Genetics, vol.7, issue.3, p.1001324, 2011. ,
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort?, Journal of Hepatology, vol.73, issue.3, pp.505-515, 2020. ,
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, Journal of Clinical Investigation, vol.115, issue.5, pp.1343-1351, 2005. ,
Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.146, issue.3, pp.726-735, 2014. ,
Exome-wide association study of plasma lipids in >300,000 individuals, Nature Genetics, vol.49, issue.12, pp.1758-1766, 2017. ,
Patatin?like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events, Hepatology Communications, vol.2, issue.7, pp.798-806, 2018. ,
Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2, Journal of Hepatology, vol.62, issue.3, pp.657-663, 2015. ,
NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects, Human Molecular Genetics, vol.27, issue.12, pp.2214-2223, 2018. ,
The dual and opposite role of theTM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis, Hepatology, vol.62, issue.6, pp.1742-1756, 2015. ,
PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease, Gastroenterology, vol.152, issue.4, pp.912-913, 2017. ,
Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk, Nature Genetics, vol.46, issue.4, pp.345-351, 2014. ,
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease, Hepatology, vol.61, issue.2, pp.506-514, 2015. ,
Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals, European Heart Journal, vol.39, issue.5, pp.385-393, 2017. ,
Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study), Scandinavian Journal of Clinical and Laboratory Investigation, vol.80, issue.2, pp.106-113, 2019. ,
, Proteases and their inhibitors, Scandinavian Journal of Clinical and Laboratory Investigation, vol.62, issue.5, pp.76-80, 2002.
Patatin?Like Phospholipase Domain?Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population, Hepatology, vol.71, issue.3, pp.820-834, 2020. ,
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease, Clinical Gastroenterology and Hepatology, vol.18, issue.4, pp.935-944.e3, 2020. ,
Association between insulin resistance and the development of cardiovascular disease, Cardiovascular Diabetology, vol.17, issue.1, p.122, 2018. ,
Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution, Nature Metabolism, vol.1, issue.6, pp.604-614, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02173578
Metabolic Inflammation?A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?, Gastroenterology, vol.158, issue.7, pp.1929-1947.e6, 2020. ,
Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research, Lipids in Health and Disease, vol.18, issue.1, p.162, 2019. ,
The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population, Journal of Clinical Lipidology, vol.10, issue.2, pp.289-298, 2016. ,
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.2, pp.644-652, 2016. ,
Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males, The American Journal of the Medical Sciences, vol.353, issue.3, pp.236-241, 2017. ,
Advances in HDL: Much More than Lipid Transporters, International Journal of Molecular Sciences, vol.21, issue.3, p.732, 2020. ,
The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state, Nature Reviews Endocrinology, vol.15, issue.12, pp.689-700, 2019. ,
Hepatic Insulin Signaling Is Required for Obesity-Dependent Expression of SREBP-1c mRNA but Not for Feeding-Dependent Expression, Cell Metabolism, vol.15, issue.6, pp.873-884, 2012. ,
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease, Journal of Clinical Investigation, vol.130, issue.3, pp.1453-1460, 2020. ,
A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis., Journal of Clinical Investigation, vol.60, issue.1, pp.265-270, 1977. ,
Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance, Nature Communications, vol.11, issue.1, p.1891, 2020. ,
URL : https://hal.archives-ouvertes.fr/inserm-02649908
Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity, Journal of Clinical Investigation, vol.127, issue.7, pp.2855-2867, 2017. ,
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity, Nature Communications, vol.9, issue.1, p.2092, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02122655
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation, Cell Metabolism, vol.26, issue.2, pp.394-406.e6, 2017. ,
Overproduction of Very Low?Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.7, pp.1225-1236, 2008. ,
Advances in lipid-lowering therapy through gene-silencing technologies, Nature Reviews Cardiology, vol.15, issue.5, pp.261-272, 2018. ,
Contribution of remnant cholesterol to cardiovascular risk, Journal of Internal Medicine, vol.288, issue.1, pp.116-127, 2020. ,
Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.134, issue.2, pp.424-431, 2008. ,
VLDL Triglyceride Kinetics in Lean, Overweight, and Obese Men and Women, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.11, pp.4151-4160, 2016. ,
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis, PLOS Medicine, vol.17, issue.3, p.e1003062, 2020. ,
Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.4, pp.1637-1646, 2016. ,
The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1859, issue.9, pp.1558-1572, 2017. ,
Molecular Distinction of Phosphatidylcholine Synthesis between the CDP-Choline Pathway and Phosphatidylethanolamine Methylation Pathway, Journal of Biological Chemistry, vol.274, issue.42, pp.29683-29688, 1999. ,
The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis, Cell Metabolism, vol.3, issue.5, pp.321-331, 2006. ,
Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis, Scientific Reports, vol.6, issue.1, 2016. ,
Impaired Hepatic Phosphatidylcholine Synthesis Leads to Cholestasis in Mice Challenged With a High-Fat Diet, Hepatology Communications, vol.3, issue.2, pp.262-276, 2019. ,
Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly, Cell Metabolism, vol.31, issue.3, pp.605-622.e10, 2020. ,
Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids, Journal of Lipid Research, vol.61, issue.8, pp.1203-1220, 2020. ,
Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction, European Heart Journal, vol.34, issue.24, pp.1826-1833, 2012. ,
Loss-of-function mutations in APOC3 and reduced risk of ischemic vascular disease, Atherosclerosis, vol.235, issue.2, p.e18, 2014. ,
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease, New England Journal of Medicine, vol.371, issue.1, pp.22-31, 2014. ,
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease, New England Journal of Medicine, vol.374, issue.12, pp.1123-1133, 2016. ,
Plasma Betatrophin Levels and Carotid Atherosclerosis, Disease Markers, vol.2019, pp.1-5, 2019. ,
ANGPTL3 Deficiency and Protection Against Coronary Artery Disease, Journal of the American College of Cardiology, vol.69, issue.16, pp.2054-2063, 2017. ,
Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.33, issue.7, pp.1529-1537, 2013. ,
APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases, Digestive Diseases and Sciences, vol.61, issue.8, pp.2284-2293, 2016. ,
Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease, New England Journal of Medicine, vol.362, issue.12, pp.1082-1089, 2010. ,
A gene variant of PNPLA3 , but not of APOC3 , is associated with histological parameters of NAFLD in an obese population, Obesity, vol.21, issue.10, pp.2138-2145, 2013. ,
Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease, Journal of Gastroenterology and Hepatology, vol.27, issue.5, pp.951-956, 2012. ,
Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population, World Journal of Gastroenterology, vol.20, issue.13, p.3655, 2014. ,
APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice, Journal of Biological Chemistry, vol.292, issue.9, pp.3692-3705, 2017. ,
Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.31, issue.3, pp.513-519, 2011. ,
PPAR? gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis, Journal of Hepatology, vol.63, issue.1, pp.164-173, 2015. ,
Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.35, issue.10, pp.2218-2224, 2015. ,
Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance, European Journal of Gastroenterology & Hepatology, vol.21, issue.11, pp.1247-1251, 2009. ,
Relationship between hepatic and systemic angiopoietin?like 3, hepatic Vitamin D receptor expression and NAFLD in obesity, Liver International, vol.40, issue.9, pp.2139-2147, 2020. ,
Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies, Scientific Reports, vol.6, issue.1, p.24013, 2016. ,
Angiopoietin-like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients, Journal of Diabetes Investigation, vol.9, issue.4, pp.952-958, 2018. ,
Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis, The American Journal of Pathology, vol.188, issue.12, pp.2800-2810, 2018. ,
Angiopoietin-like protein 8 (betatrophin) is a stress-response protein that down-regulates expression of adipocyte triglyceride lipase, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol.1861, issue.2, pp.130-137, 2016. ,
Lipoprotein lipase: Biosynthesis, regulatory factors, and its role in atherosclerosis and other diseases, Clinica Chimica Acta, vol.480, pp.126-137, 2018. ,
Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease, Journal of Clinical Medicine, vol.7, issue.11, p.378, 2018. ,
Selective Retention of VLDL, IDL, and LDL in the Arterial Intima of Genetically Hyperlipidemic Rabbits In Vivo, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.15, issue.4, pp.534-542, 1995. ,
Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases, Oxidative Medicine and Cellular Longevity, vol.2017, pp.1-10, 2017. ,
HDL flux is higher in patients with nonalcoholic fatty liver disease, American Journal of Physiology-Endocrinology and Metabolism, vol.317, issue.5, pp.E852-E862, 2019. ,
Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?, Clinica Chimica Acta, vol.412, issue.7-8, pp.587-592, 2011. ,
Nonalcoholic fatty liver disease and statins, Metabolism, vol.64, issue.10, pp.1215-1223, 2015. ,
Reply to ?statins and non-alcoholic steatohepatitis?, Metabolism, vol.66, pp.e3-e5, 2017. ,
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial, The Journal of Clinical Endocrinology & Metabolism, vol.102, issue.8, pp.2950-2961, 2017. ,
Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality, Hepatology Communications, vol.2, issue.10, pp.1227-1234, 2018. ,
Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients, BMC Medical Genomics, vol.12, issue.1, p.80, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02154999
Liver fat accumulation is associated with circulating PCSK9, Annals of Medicine, vol.48, issue.5, pp.384-391, 2016. ,
Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice, Journal of Biological Chemistry, vol.294, issue.23, pp.9037-9047, 2019. ,
Low Level of Low-Density Lipoprotein Receptor-Related Protein 1 Predicts an Unfavorable Prognosis of Hepatocellular Carcinoma after Curative Resection, PLoS ONE, vol.7, issue.3, p.e32775, 2012. ,
Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice, JHEP Reports, vol.1, issue.6, pp.418-429, 2019. ,
Low-density lipoprotein receptor?related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression, Journal of Biological Chemistry, vol.293, issue.25, pp.9674-9684, 2018. ,
Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol, Blood, vol.103, issue.10, pp.3777-3782, 2004. ,
Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance, Atherosclerosis, vol.204, issue.1, pp.105-111, 2009. ,
The Role of Cholesterol in the Pathogenesis of NASH, Trends in Endocrinology & Metabolism, vol.27, issue.2, pp.84-95, 2016. ,
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis, Cell Metabolism, vol.31, issue.5, pp.969-986.e7, 2020. ,
Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent, Journal of Hepatology, vol.61, issue.6, pp.1376-1384, 2014. ,
Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review, Nutrients, vol.11, issue.12, p.3064, 2019. ,
Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease, Proceedings of the National Academy of Sciences, vol.117, issue.13, pp.7347-7354, 2020. ,
An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans, Cell Metabolism, vol.27, issue.3, pp.559-571.e5, 2018. ,
A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease, Medicine, vol.98, issue.12, p.e14918, 2019. ,
Exercise Training Reduces Liver Fat and Increases Rates of VLDL Clearance But Not VLDL Production in NAFLD, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.11, pp.4219-4228, 2016. ,
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis, Gastroenterology, vol.149, issue.2, pp.367-378.e5, 2015. ,
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, vol.51, issue.1, pp.121-129, 2009. ,
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients, Gastroenterology, vol.149, issue.2, pp.379-388, 2015. ,
Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease, Annals of Surgery, vol.260, issue.5, pp.893-899, 2014. ,
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis, Gastroenterology, vol.159, issue.4, pp.1290-1301.e5, 2020. ,
The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis, The Journal of Pediatrics, vol.180, pp.31-37.e2, 2017. ,
The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: ?NASHOST? prospective observational trial, Surgery for Obesity and Related Diseases, vol.11, issue.6, pp.1315-1322, 2015. ,
Origin and Evolution of Distinct Isotopic Variabilities for Sr, Mo, and Nd within CC and NC Reservoirs, Goldschmidt Abstracts, 2020. ,
Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis, Frontiers in Physiology, vol.7, issue.344, 2016. ,
Bariatric surgery, lipoprotein metabolism and cardiovascular risk, Current Opinion in Lipidology, vol.26, issue.4, pp.317-324, 2015. ,
Weight and Metabolic Outcomes 12 Years after Gastric Bypass, New England Journal of Medicine, vol.377, issue.12, pp.1143-1155, 2017. ,
Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity, JAMA, vol.322, issue.13, p.1271, 2019. ,
Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study, The Lancet Diabetes & Endocrinology, vol.7, issue.10, pp.786-795, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02568049
Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.152, issue.7, pp.1679-1694.e3, 2017. ,
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, The Lancet, vol.385, issue.9972, pp.956-965, 2015. ,
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebocontrolled phase 3 trial, Lancet, vol.394, pp.2184-2196, 2019. ,
Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low?Density Lipoprotein Cholesterol, Hepatology Communications, vol.3, issue.11, pp.1472-1481, 2019. ,
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis, Journal of Hepatology, vol.72, issue.1, pp.25-33, 2020. ,
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients, Liver International, vol.39, issue.11, pp.2082-2093, 2019. ,
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial, Hepatology, vol.72, issue.1, pp.58-71, 2020. ,
Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives, Endocrine Reviews, vol.39, issue.6, pp.960-989, 2018. ,
Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease, Clinical Biochemistry, vol.45, issue.9, pp.655-658, 2012. ,
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet, vol.391, issue.10126, pp.1174-1185, 2018. ,
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis, Hepatology, vol.71, issue.4, pp.1198-1212, 2019. ,
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis, Hepatology, vol.71, issue.4, pp.1198-1212, 2019. ,
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis, Journal of Hepatology, vol.70, issue.4, pp.735-744, 2019. ,
Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis, Journal of Lipid Research, vol.60, issue.3, pp.550-565, 2019. ,
Serum Levels of Fibroblast Growth Factor 19 Are Inversely Associated with Coronary Artery Disease in Chinese Individuals, PLoS ONE, vol.8, issue.8, p.e72345, 2013. ,
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study, Journal of Hepatology, vol.73, issue.2, pp.231-240, 2020. ,
Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial, Hepatology, vol.56, issue.3, pp.922-932, 2012. ,
Distinct but complementary contributions of PPAR isotypes to energy homeostasis, Journal of Clinical Investigation, vol.127, issue.4, pp.1202-1214, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01709972
Fibrates and future PPAR? agonists in the treatment of cardiovascular disease, Nature Clinical Practice Cardiovascular Medicine, vol.5, issue.9, pp.542-553, 2008. ,
PPARs and nonalcoholic fatty liver disease, Biochimie, vol.136, pp.65-74, 2017. ,
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis, JAMA Internal Medicine, vol.177, issue.5, p.633, 2017. ,
Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial, Gastroenterology, vol.135, issue.1, pp.100-110, 2008. ,
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology, vol.51, issue.2, pp.445-453, 2009. ,
Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges, Hepatology, vol.65, issue.3, pp.1058-1061, 2017. ,
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus, Annals of Internal Medicine, vol.165, issue.5, p.305, 2016. ,
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes, Clinical Gastroenterology and Hepatology, vol.16, issue.4, pp.558-566.e2, 2018. ,
A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia: Response to Bell and Brunzell, Diabetes Care, vol.28, issue.12, pp.2985-2986, 2005. ,
Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis, Diabetology & Metabolic Syndrome, vol.9, issue.1, p.90, 2017. ,
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, The Lancet, vol.366, issue.9493, pp.1279-1289, 2005. ,
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses, BMJ, vol.368, p.l7078, 2020. ,
Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials, Cardiovascular Diabetology, vol.16, issue.1, p.134, 2017. ,
Pioglitazone After Ischemic Stroke or Transient Ischemic Attack, Journal of Vascular Surgery, vol.64, issue.1, p.260, 2016. ,
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis, New England Journal of Medicine, vol.362, issue.18, pp.1675-1685, 2010. ,
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial, Alimentary Pharmacology & Therapeutics, vol.49, issue.9, pp.1205-1213, 2019. ,
NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels, Alimentary Pharmacology & Therapeutics, vol.41, issue.3, pp.301-309, 2014. ,
The Peroxisome Proliferator-Activated Receptor-? Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-??Dependent Manner In Vitro and In Vivo in Mice, Journal of the American College of Cardiology, vol.52, issue.10, pp.869-881, 2008. ,
Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone, Biochemical and Biophysical Research Communications, vol.278, issue.3, pp.704-711, 2000. ,
MBX-8025, A Novel Peroxisome Proliferator Receptor-? Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.9, pp.2889-2897, 2011. ,
Elafibranor, an Agonist of the Peroxisome Proliferator?Activated Receptor?? and ??, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening, Gastroenterology, vol.150, issue.5, pp.1147-1159.e5, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02648787
Dual PPAR?/? agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models, Liver International, vol.38, issue.6, pp.1084-1094, 2017. ,
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) // Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate, Journal of Medicinal Chemistry, vol.61, issue.6, pp.2246-2265 ,
Fibroblast Growth Factor 21?Metabolic Role in Mice and Men, Endocrine Reviews, vol.38, issue.5, pp.468-488, 2017. ,
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial, The Lancet, vol.392, issue.10165, pp.2705-2717, 2018. ,
Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice, Circulation, vol.131, issue.21, pp.1861-1871, 2015. ,
Fibroblast growth factor 21 inhibits atherosclerosis in apoE?/? mice by ameliorating Fas-mediated apoptosis, Lipids in Health and Disease, vol.17, issue.1, p.203, 2018. ,
Thyroid Hormone Signaling and the Liver, Hepatology, vol.72, issue.2, pp.742-752, 2020. ,
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet, vol.394, issue.10213, pp.2012-2024, 2019. ,
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, The Lancet, vol.387, issue.10019, pp.679-690, 2016. ,
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.4, pp.311-322, 2016. ,
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.19, pp.1834-1844, 2016. ,
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE?/? and LDLr?/? Mice by a Mechanism That Includes Inflammatory Pathways, JACC: Basic to Translational Science, vol.3, issue.6, pp.844-857, 2018. ,
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice, Diabetologia, vol.54, issue.10, pp.2649-2659, 2011. ,
GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice, PLoS ONE, vol.7, issue.11, p.e49152, 2012. ,
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.155, issue.5, pp.1463-1473.e6, 2018. ,